Altre lingue Nova Mentis Life Science Corp.

Azioni

NOVA

CA66980V1067

Mercato chiuso - Canadian Securities Exchange Altri mercati azionari 21:38:53 25/04/2024			Variaz. 5gg	Var. 1 gen.
0,015 ^CAD	0,00%		+50,00%	-25,00%

08/04	Nova Mentis Life Science Corp. riporta i risultati degli utili per l'intero anno conclusosi il 31 dicembre 2023	CI
26/02	Nova Mentis Life Science Corp. annuncia la nomina di Steve Loutskou nel Consiglio di Amministrazione	CI

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Nova Mentis Life Science Corp. Reports Earnings Results for the Full Year Ended December 31, 2023	08/04
Nova Mentis Life Science Corp. Announces the Appointment of Steve Loutskou to the Board of Directors	26/02
Nova Mentis Announces Change of Directors	26/02
Nova Mentis Life Science Corp. Announces Management Changes	04/01
Nova Mentis Life Science Corp. Announces Resignation of Dr. Stephen Glazer as Chief Scientific Officer and Director	11/12
Nova Mentis Life Science Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	29/11
Nova Mentis Life Science Corp.: Nova Mentis begrüßt Entscheidung der Regierung zur Einrichtung einer Beratergruppe für seltene Krankheiten	03/11
Nova Mentis Applauds Government Decision to Create Rare Disease Advisory Group	03/11
Nova Mentis Life Science Corp. - Participant Screening Underway in Canada's First Psilocybin Clinical Trial for Fragile X Syndrome	31/08/23
Nova Mentis Life Science Corp. Announces Participant Screening Underway in Canada's First Psilocybin Clinical Trial for Fragile X Syndrome	30/08/23
Nova Mentis Life Science Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	29/08/23
Nova Mentis Life Science Corp. Reports Earnings Results for the First Quarter Ended March 31, 2023	31/05/23
Nova Mentis Life Science Corp. Reports Earnings Results for the Full Year Ended December 31, 2022	25/04/23
Nova Mentis Life Science Corp. Auditor Raises 'Going Concern' Doubt	25/04/23
Nova Mentis Begins Recruitment in First-of-its-Kind Health Canada Psilocybin Trial	19/04/23
KGK Science Inc. Begins Recruitment in First-of-its-Kind Health Canada Approved Psilocybin Trial	18/04/23
KGK Sciences Inc. Begins Recruiting Participants, on Behalf of Client Nova Mentis Life Science Corp. in First-Ever Clinical Trial Investigating Effects of Psilocybin on Adults Diagnosed with Fragile X Syndrome	18/04/23
Nova Mentis Receives Institutional Review Board Approval to Commence Psilocybin Clinical Trial	12/04/23
Nova Mentis Life Science Corp. Receives Institutional Review Board Approval to Commence Psilocybin Clinical Trial	11/04/23
Nova Mentis Provides Corporate Update and 2023 Outlook	06/04/23

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Nova Mentis Life Science Corp.

Azioni

NOVA

CA66980V1067

Altre lingue

Filtri